

1 **Evaluation of Reproducibility in Urology Publications**

2 Shelby Lynn Rauh, MS¹, Bradley S. Johnson, MA¹, Aaron Bowers BS¹, Daniel Tritz, MS¹,

3 Benjamin Matthew Vassar, PhD¹

4 ¹Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.

5

6 **Corresponding Author:** Mrs. Shelby Lynn Rauh, Oklahoma State University Center for Health

7 Sciences, 1111 W 17th St., Tulsa, OK 74107, USA; email: shelby.rauh@okstate.edu

8 **Conflicts of Interest and Source of Funding:** This study was funded through the 2019

9 Presidential Research Fellowship Mentor–Mentee Program at Oklahoma State University Center
10 for Health Sciences.

11

12 **Keywords:** Cross-Sectional, Reproducibility, Urology

13

14 **Take Home Message (17/40 words):** Many components of transparency and reproducibility are
15 lacking in urology publications, making study replication, at best, difficult.

16

17 **Introduction:** Reproducibility is essential for the integrity of scientific research. Reproducibility
18 is measured by the ability of investigators to replicate the outcomes of an original publication by
19 using the same materials and procedures.

20 **Methods:** We sampled 300 publications in the field of urology for assessment of multiple
21 indicators of reproducibility, including material availability, raw data availability, analysis script
22 availability, pre-registration information, links to protocols, and whether the publication was
23 freely available to the public. Publications were also assessed for statements about conflicts of
24 interest and funding sources.

25 **Results:** Of the 300 sample publications, 171 contained empirical data and could be analyzed for
26 reproducibility. Of the analyzed articles, 0.58% (1/171) provided links to protocols, and none of
27 the studies provided analysis scripts. Additionally, 95.91% (164/171) did not provide accessible
28 raw data, 97.53% (158/162) did not provide accessible materials, and 95.32% (163/171) did not
29 state they were pre-registered.

30 **Conclusion:** Current urology research does not consistently provide the components needed to
31 reproduce original studies. Collaborative efforts from investigators and journal editors are
32 needed to improve research quality, while minimizing waste and patient risk.

33

34 **Introduction**

35 Reproducibility is determined by the availability of materials, raw data, analysis procedures, and
36 protocols used to conduct original research so that other researchers may replicate the findings; it
37 is crucial to establishing credible and reliable research that ultimately governs clinical practice.
38 Recent evidence suggests that up to 90% of preclinical research may not be reproducible.[1] A
39 recent survey of over 1500 researchers concurred with this assessment, with the vast majority
40 believing that biomedical research is experiencing a “reproducibility crisis”.[2] Several
41 explanations have been offered for why reproducibility has become an issue, with pressure to
42 publish and the race to be the first to report new findings being among the most likely causes.[3]
43 When research is not reproducible, time and money are wasted reproducing erroneous results,
44 and patients may be exposed to ineffective or harmful therapies.[4] Concerns about
45 reproducibility span from preclinical to clinical research.

46
47 The field of prostate cancer research serves as an example. On the diagnostic side, *in vitro*
48 studies are performed on prostate biopsy samples to advance understanding of early detection
49 and diagnosis. However, widespread misuse of immunohistochemical staining exists, which
50 contributes to the lack of research reproducibility. Sfanos *et al*[5] argued that the ubiquitously
51 used research-grade antibodies within the biomedical research community (as opposed to clinical
52 grade used for patient diagnosis) are not routinely validated in the investigators’ laboratories,
53 which may lead to variable results that cannot be reproduced in subsequent studies. On the other
54 end of the research spectrum, randomized clinical trials are conducted to evaluate the efficacy of
55 new therapeutic agents for prevention or treatment of prostate cancer. In one large-scale
56 randomized trial, Thompson *et al*[6] compared the effects of finasteride against placebo for

57 prostate cancer prevention. These investigators found that finasteride prevented or delayed the
58 development of prostate cancer but also led to an increased risk of higher-grade cancer upon
59 detection. The raw data from this clinical trial were not made entirely available because of
60 patient privacy and data “messiness”. Some investigators attempted to reanalyze the trial data,
61 but the results were mixed[7,8]. Since then, Baker *et al*[9] proposed a method to overcome
62 issues of privacy and messiness, while also fostering reproducibility of the trial outcomes.

63
64 Thus, when a study does not report the components needed to reproduce it, or when studies are
65 not replicated by other researchers, determining the credibility of the original findings is
66 hindered. Our study examines existing research in urology and determines how often studies
67 include markers of reproducibility and how frequently studies are replicated. This research
68 highlights the issue of reproducibility in urology, a field in which the topic has not been well
69 explored. We anticipate that our findings will prompt discussions among investigators and
70 journal editors, which may lead to improvement in the quality of research in the field.

71

72 **Methods**

73 We used an observational, cross-sectional study design, drawing on the methodology of
74 Hardwicke *et al*[10], with modifications. This study did not involve human participants and was
75 not subject to oversight or approval by an institutional review board.[11] We report our study in
76 accordance with previously published guidelines for meta-epidemiological methodology
77 research.[12] To foster transparency and reproducibility, we have uploaded our protocol, data
78 extraction form, and other materials for public viewing on the Open Science Framework (OSF;
79 <https://osf.io/n4yh5/>).

80

81 *Journal Selection*

82 We used the National Library of Medicine (NLM) catalog to search for all relevant journals,
83 using the subject terms tag Urology[ST]. The search was performed on 30 May 2019. The
84 inclusion criteria required journals to have full-text publications in English and be MEDLINE
85 indexed. The list of journals in the NLM catalog fitting the inclusion criteria were then extracted
86 using the electronic International Standard Serial Number (ISSN) or the linking ISSN when the
87 electronic ISSN was unavailable. PubMed was searched with the list of ISSNs to identify all
88 articles published from 1 January 2014 to 31 December 2018. We randomly sampled 300
89 publications that met the inclusion criteria (<https://osf.io/csf5t/>).

90

91 *Data Extraction Training*

92 The two investigators responsible for data extraction (S.R. and B.J.) underwent a full day of
93 training to ensure adequate interrater reliability. The training included an in-person session to
94 review the project study design, protocol, data extraction form, and examples of where
95 information may be contained using two example publications. The investigators were then
96 given three example publications from which to extract data in a blinded fashion. Afterward, the
97 pair reconciled differences in their results. This training session was recorded from the
98 presenter's point of view (D.T.) and listed online for reference (<https://osf.io/tf7nw/>). As a final
99 training exercise, investigators extracted data from the first 10 publications of the full sample and
100 then met to reconcile any differences in the data before proceeding to extraction of the remaining
101 290 publications.

102

103 *Data Extraction*

104 Data extraction on the remaining 290 publications was conducted in a duplicate, blinded fashion.
105 A final consensus meeting was held with both investigators to resolve disagreements. A third
106 investigator (D.T.) was available for adjudication but was not needed. Data were extracted using
107 a pilot-tested Google form based on Hardwicke *et al*, with modifications.[10] This form
108 contained information necessary for a study to be reproducible, such as the availability of
109 materials, data, protocols, or analysis scripts (<https://osf.io/3nfa5/>). The data extracted varied
110 based on the study design, with studies having no empirical data being excluded (e.g., editorials,
111 commentaries [without reanalysis], simulations, news, reviews, and poems) (Table 1). The form
112 also included the 5-year impact factor and that of the most recent year available and expanded
113 the study design options to include cohort studies, case series, secondary analyses, chart reviews,
114 and cross-sectional studies. Funding options were also expanded to include university, hospital,
115 public, private/industry, non-profit, or mixed funding.

116

117 *Evaluation of Open Access Status*

118 We evaluated all 300 publications to determine whether they were freely available online
119 through open access. We searched Open Access Button (openaccessbutton.org) with publication
120 titles and DOI numbers. This tool actively searches for the full-text online. If it could not find a
121 publication, two of us (S.R. and B.J.) searched Google Scholar and PubMed to determine if the
122 full text was available via open access on the journal website.

123

124 *Evaluation of Replication and Whether Publications Were Included in Research Synthesis*

125 For empirical studies, excluding meta-analysis and commentary with analysis, we searched the
126 Web of Science to determine whether the publication was cited in a replication study, meta-
127 analysis, or systematic review. The Web of Science additionally lists information important for
128 our study, such as the country of journal publication, 5-year impact factor (when available), and
129 most recent impact factor.

130

131 *Statistical Analysis*

132 We report descriptive statistics for each of our findings with 95% confidence intervals (95% CIs)
133 using analysis functions within Microsoft Excel.

134

135 **Results**

136 *Included Sample and Characteristics*

137 Our inclusion criteria resulted in 42,422 articles from 46 urology journals found in the NLM
138 catalog. Of the articles meeting the inclusion criteria, 300 articles were randomly chosen for
139 analysis. Six articles were not analyzed because we did not have access to the text. The
140 remaining 294 articles were assessed to determine the 5-year impact factor of their
141 corresponding journals. Twenty of the 294 articles came from journals without 5-year impact
142 factors. Thus, journals of the 274 studies reported a median of 2.466 as their 5-year impact factor
143 with an interquartile range of 1.898 to 4.925. In addition, a full assessment of the original 300
144 articles revealed that 88 (29.33%) were accessible through Open Access Button or other means.
145 Over half of our included studies (163/294, 55.44%) provided a statement revealing that their
146 study was without a conflict of interest. However, 95 (32.31%) of our included studies did not
147 provide any type of conflict of interest statement. Nearly two-thirds of our studies (185, 62.93%)

148 did not state if or from where they received funding. Among the 109 studies that provided a
149 statement, most did not receive funding (31, 28.44%). Of the 78 studies that did receive funding,
150 most obtained it through public entities (23, 29.49%). Other characteristics of our included
151 studies can be found in Table 2 and Supplementary Table 1.

152

153 *Characteristics Associated with Reproducibility*

154 The only studies that were assessed for reproducibility were those that had empirical data. Thus,
155 115 articles without empirical data were excluded from the initial 294 studies. We also excluded
156 eight case studies and case series because such studies cannot be reproduced. We therefore
157 assessed a total of 171 studies for reproducibility. Of these studies, 163 (95.32%) did not provide
158 a pre-registration statement. Among the 8 studies that provided a pre-registration statement, 4
159 had accessible links to the pre-registration. Nearly all analyzed studies omitted a data availability
160 statement (162/171, 94.74%). Of the 9 studies that provided a data statement, 2 claimed that their
161 data was not available. None of the 7 studies that claimed their data were available provided
162 enough raw data for the study to be reproduced. Similarly, 156 (96.30%) of 162 analyzed studies
163 (excluding meta-analyses) did not provide a material availability statement. Six studies provided
164 a material availability statement; five of these publications included a statement that materials
165 were available, but only four provided working links to the materials. Only one of the 171
166 studies included a full protocol in the publication, and none of the 171 studies provided an
167 analysis script availability statement. More characteristics associated with reproducibility are
168 presented in Supplementary Table 1.

169

170 **Discussion**

171 Our study revealed concerning findings regarding the reproducibility of research in urology
172 literature. Only nine studies made statements regarding the availability of data, and only seven of
173 those actually made their data available. Fewer than half of the studies in our sample were
174 available through Open Access Button, and detailed protocols and pre-registration were rare.
175 One trial in our sample was claimed to be a replication of a previous study, but even this
176 publication failed to include any of the reproducibility markers that we assessed. These findings
177 are similar to those of Hardwicke *et al*[10] for a survey of reproducibility in social sciences.

178
179 Our study revealed that only one study contained a link to protocols, while no studies provided
180 analysis scripts and only six provided materials statements. These elements are the three most
181 important ones in reproducing a study. Protocols provide details about how each step of the study
182 was performed, to an extent much deeper than would be relevant to the average person reading
183 the methods section.[13,14] Similarly, analysis scripts are crucial for re-creating the original
184 analysis in a stepwise manner.[15] Materials include anything that was necessary for the study to
185 be performed, including forms, questionnaires, devices, software programs, and more.[16] Some
186 investigators have posited that freely providing these elements invites plagiarism of study design,
187 a major concern with the pressure on researchers to publish while limiting time and funding.[17]
188 Chan *et al*[18] have suggested placing protocols in a lockbox and making them available upon
189 data release to protect intellectual property, while maintaining reproducible research. At the very
190 least, authors should state in their articles that these crucial elements of reproducibility are
191 available upon reasonable request.

192

193 Pre-registration is one of the best ways to increase transparency and reproducibility in research,
194 yet only eight studies from our sample were pre-registered. Pre-registration of trials encourages
195 transparency in research by outlining the intended outcomes, interventions, protocols, and
196 methods of analysis before the study is underway.[19] When trials are not pre-registered,
197 investigators have the freedom to manipulate data to obtain significance (P-hacking)[20],
198 hypothesize after results are known (HARKing)[21], switch primary outcomes[22], or deviate
199 from a priori protocols.[23] Several researchers, including Nosek *et al*[24] have called for
200 widespread adoption of pre-registration, citing its value in increasing transparency, rigor, and
201 reproducibility. Early results of pre-registration are positive, with pre-registered studies
202 exhibiting a significant increase in null findings.[25] The OSF hosts pre-registration free of
203 charge and also provides pre-registration templates and instructional guides.[26,27] High-impact
204 journals could require pre-registration for any study to be considered for publication, which
205 would encourage authors to take the necessary steps to increase the chance of having their
206 research published in a respected journal.

207

208 Data availability is another area in which urology research falls short. Some journals, including
209 *European Urology*, have begun to require that authors' manuscripts include a description of how
210 readers can access underlying data, while other journals mandate the inclusion of study
211 protocols, analysis scripts, and any other element needed to replicate the original study.[28,29]
212 Beginning in 2019, the International Committee of Medical Journal Editors (ICMJE) mandated
213 data sharing statements by all prospective clinical trials submitted for publication to an ICMJE
214 member journal.[30] Showing that such policies can be successful, *PLoS One*, another journal
215 requiring data availability, reported that 20% of studies published in the journal hosted their data

216 on a third-party website, 60% provided their data in a supplement, and the remaining 20% made
217 their data available upon reasonable request.[31] These initiatives are steps in the right direction,
218 and we propose a few more possibilities for improving reproducibility in urology research.

219

220 The Repeat framework was designed by McIntosh *et al*[32] to improve reproducibility in
221 research. This easy-to-use checklist can be adapted for most studies. Additionally, the OSF
222 developed the Transparency and Openness Promotion (TOP) Guidelines, which provide eight
223 modular standards designed to increase transparency, disclosure, openness, and
224 collaboration.[33] The EQUATOR network has set out to improve research reporting and
225 manuscript writing through the use of reporting guidelines.[34,35] These guidelines, available
226 for nearly every type of study, ensure that manuscripts are written in a transparent way,
227 encouraging reproducibility and accurate reporting of findings.[12] Some journals have begun to
228 require the use of reporting guidelines in the studies they publish.[36–38]

229

230 Our study has both strengths and limitations. Regarding strengths, we applied double data
231 extraction procedures, which is considered a best practice methodology by the systematic review
232 community and is recommended in the *Cochrane Handbook for Systematic Reviews of*
233 *Interventions*.[44] To foster study reproducibility and transparency, we have made all relevant
234 study materials publicly available on OSF. Concerning limitations, our study is cross-sectional in
235 nature, including only PubMed-indexed journals that were published in English during a finite
236 time period. Thus, our results should be interpreted in light of these considerations. Additionally,
237 many replication studies are not published because they are never submitted for publication.[2]
238 In recent years, some organizations, including Elsevier, have encouraged the submission and

239 publication of replication studies, but they are not yet common in biomedical literature.[45] We
240 did not attempt to contact authors for data availability, analysis scripts, protocols, or any of the
241 other markers of reproducibility. While we may have found these things to be readily available,
242 it is more likely that we would have run up against the familiar issues of low response rate and
243 limited cooperation.[46,47]

244

245 **Conclusion**

246 Current urology research does not consistently provide the components needed to reproduce
247 original studies. Collaborative efforts from investigators and journal editors are needed to
248 improve research quality, while minimizing waste and patient risk.

249

250

251 **References**

- 252 1. Begley CG, Glenn Begley C, Ioannidis JPA. Reproducibility in Science [Internet]. Vol. 116,
253 Circulation Research. 2015. p. 116–26. Available from:
254 <http://dx.doi.org/10.1161/circresaha.114.303819>
- 255 2. Baker M. Is there a reproducibility crisis? A Nature survey lifts the lid on how researchers view
256 the 'crisis rocking science and what they think will help. *Nature*. 2016;533(7604):452–5.
- 257 3. Eisner DA. Reproducibility of science: Fraud, impact factors and carelessness. *J Mol Cell Cardiol*.
258 2018 Jan;114:364–8.
- 259 4. Loscalzo J. Irreproducible experimental results: causes, (mis)interpretations, and consequences.
260 *Circulation*. 2012 Mar 13;125(10):1211–4.
- 261 5. Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, et al. If this is true,
262 what does it imply? How end-user antibody validation facilitates insights into biology and disease.
263 *Asian J Urol*. 2019 Jan;6(1):10–25.
- 264 6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of
265 finasteride on the development of prostate cancer. *N Engl J Med*. 2003 Jul 17;349(3):215–24.
- 266 7. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride
267 does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer*
268 *Prev Res* . 2008 Aug;1(3):174–81.
- 269 8. Shepherd BE, Redman MW, Ankerst DP. Does Finasteride Affect the Severity of Prostate Cancer?
270 A Causal Sensitivity Analysis. *J Am Stat Assoc*. 2008 Dec 1;103(484):1392–404.
- 271 9. Baker SG, Darke AK, Pinsky P, Parnes HL, Kramer BS. Transparency and reproducibility in data
272 analysis: the Prostate Cancer Prevention Trial. *Biostatistics*. 2010 Jul;11(3):413–8.
- 273 10. Hardwicke TE, Wallach JD, Kidwell M, Ioannidis J. An empirical assessment of transparency and
274 reproducibility-related research practices in the social sciences (2014-2017) [Internet]. 2019.
275 Available from: <http://dx.doi.org/10.31222/osf.io/6uhg5>
- 276 11. eCFR — Code of Federal Regulations [Internet]. [cited 2019 Jun 27]. Available from:
277 [https://www.ecfr.gov/cgi-](https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML)
278 [bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&](https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML)
279 [r=PART&ty=HTML](https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML)
- 280 12. Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. *Evid*
281 *Based Med*. 2017 Aug;22(4):139–42.
- 282 13. Jirge PR. Preparing and Publishing a Scientific Manuscript. *J Hum Reprod Sci*. 2017 Jan;10(1):3–9.
- 283 14. Jundi AA, Al Jundi A. Protocol Writing in Clinical Research [Internet]. *JOURNAL OF CLINICAL*
284 *AND DIAGNOSTIC RESEARCH*. 2016. Available from:
285 <http://dx.doi.org/10.7860/jcdr/2016/21426.8865>
- 286 15. Piccolo SR, Frampton MB. Tools and techniques for computational reproducibility. *Gigascience*.
287 2016 Jul 11;5(1):30.

- 288 16. Reddy P, Bhadauria U. Integral elements of a research protocol [Internet]. Vol. 31, Journal of Indian
289 Academy of Oral Medicine and Radiology. 2019. p. 167. Available from:
290 http://dx.doi.org/10.4103/jiaomr.jiaomr_220_18
- 291 17. Ross S, Magee L, Walker M, Wood S. Protecting intellectual property associated with Canadian
292 academic clinical trials--approaches and impact. *Trials*. 2012 Dec 27;13:243.
- 293 18. Chan A-W, Hróbjartsson A. Promoting public access to clinical trial protocols: challenges and
294 recommendations. *Trials*. 2018 Feb 17;19(1):116.
- 295 19. Mistler S. Planning your analyses: Advice for avoiding analysis problems in your research.
296 *Psychological Science Agenda*. 2012;26(11).
- 297 20. Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: undisclosed flexibility in data
298 collection and analysis allows presenting anything as significant. *Psychol Sci*. 2011
299 Nov;22(11):1359–66.
- 300 21. Kerr NL. HARKing: hypothesizing after the results are known. *Pers Soc Psychol Rev*.
301 1998;2(3):196–217.
- 302 22. Howard B, Scott JT, Blubaugh M, Roepke B, Scheckel C, Vassar M. Systematic review: Outcome
303 reporting bias is a problem in high impact factor neurology journals. *PLoS One*. 2017 Jul
304 20;12(7):e0180986.
- 305 23. Ghooi RB, Bhosale N, Wadhvani R, Divate P, Divate U. Assessment and classification of protocol
306 deviations. *Perspect Clin Res*. 2016 Jul;7(3):132–6.
- 307 24. Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The preregistration revolution. *Proc Natl Acad
308 Sci U S A*. 2018 Mar 13;115(11):2600–6.
- 309 25. Allen C, Mehler DMA. Open science challenges, benefits and tips in early career and beyond. *PLoS
310 Biol*. 2019 May;17(5):e3000246.
- 311 26. OSF [Internet]. [cited 2019 Jul 12]. Available from: <https://osf.io/>
- 312 27. Templates of OSF Registration Forms. 2016 Oct 31 [cited 2019 Jul 18]; Available from:
313 <https://osf.io/zab38/wiki/home/>
- 314 28. Myers MG Jr, Diabetes Editorial Team. Diabetes Takes New Steps to Increase Transparency and
315 Reproducibility. *Diabetes*. 2019 Apr;68(4):681–2.
- 316 29. Guide for Authors: European Urology.
- 317 30. Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data Sharing Statements for
318 Clinical Trials — A Requirement of the International Committee of Medical Journal Editors
319 [Internet]. Vol. 376, *New England Journal of Medicine*. 2017. p. 2277–9. Available from:
320 <http://dx.doi.org/10.1056/nejme1705439>
- 321 31. 0000-0003-1953-, 0000-0002-7378-. Making Progress Toward Open Data: Reflections on Data
322 Sharing at PLOS ONE | EveryONE: The PLOS ONE blog [Internet]. *EveryONE*. 2017 [cited 2019
323 Jul 16]. Available from: [https://blogs.plos.org/everyone/2017/05/08/making-progress-toward-open-](https://blogs.plos.org/everyone/2017/05/08/making-progress-toward-open-data/)
324 [data/](https://blogs.plos.org/everyone/2017/05/08/making-progress-toward-open-data/)

- 325 32. McIntosh LD, Juehne A, Vitale CRH, Liu X, Alcoser R, Lukas JC, et al. Repeat: a framework to
326 assess empirical reproducibility in biomedical research. *BMC Med Res Methodol*. 2017 Sep
327 18;17(1):143.
- 328 33. Nosek BA, Alter G, Banks GC, Borsboom D, Bowman SD, Breckler SJ, et al. Transparency and
329 Openness Promotion (TOP) Guidelines [Internet]. 2016. Available from:
330 <http://dx.doi.org/10.1126/science.aab2374>
- 331 34. Carpenter CR, Meisel ZF. Overcoming the Tower of Babel in Medical Science by Finding the
332 “EQUATOR”: Research Reporting Guidelines. *Acad Emerg Med* [Internet]. 2017 May 11;
333 Available from: <http://dx.doi.org/10.1111/acem.13225>
- 334 35. The EQUATOR Network | Enhancing the QUALity and Transparency Of Health Research [Internet].
335 [cited 2017 Jun 16]. Available from: <http://www.equator-network.org/>
- 336 36. Jorski A, Scott J, Heavener T, Vassar M. Reporting guideline and clinical trial registration
337 requirements in gastroenterology and hepatology journals. *Int J Evid Based Healthc*. 2018
338 Jun;16(2):119–27.
- 339 37. Sims MT, Bowers AM, Fernan JM, Dormire KD, Herrington JM, Vassar M. Trial registration and
340 adherence to reporting guidelines in cardiovascular journals. *Heart*. 2018 May;104(9):753–9.
- 341 38. Sims MT, Henning NM, Wayant CC, Vassar M. Do emergency medicine journals promote trial
342 registration and adherence to reporting guidelines? A survey of “Instructions for Authors.” *Scand J*
343 *Trauma Resusc Emerg Med*. 2016 Nov 24;24(1):137.
- 344 39. Wan J, Cain MP, Tanaka S, Nelson C. Conflict of Interest, Self-Reporting and Our Profession. *J*
345 *Urol*. 2019 Apr;201(4):678–9.
- 346 40. Carlisle A, Bowers A, Wayant C, Meyer C, Vassar M. Financial Conflicts of Interest Among
347 Authors of Urology Clinical Practice Guidelines. *Eur Urol*. 2018 Sep;74(3):348–54.
- 348 41. Jimbo M, Granberg CF, Osumah TS, Bandari J, Cannon GM, Routh JC, et al. Discrepancies in Self-
349 Reported and Actual Conflicts of Interest for Robotic Pediatric Urological Surgery. *J Urol*. 2019
350 Feb;201(2):393–9.
- 351 42. Lotbiniere-Bassett MP de, de Lotbiniere-Bassett MP, Riva-Cambrin J, McDonald PJ. Conflict of
352 interest policies and disclosure requirements in neurosurgical journals [Internet]. Vol. 131, *Journal of*
353 *Neurosurgery*. 2019. p. 264–70. Available from: <http://dx.doi.org/10.3171/2018.4.jns172751>
- 354 43. Shawwa K, Kallas R, Koujanian S, Agarwal A, Neumann I, Alexander P, et al. Requirements of
355 Clinical Journals for Authors’ Disclosure of Financial and Non-Financial Conflicts of Interest: A
356 Cross Sectional Study [Internet]. Vol. 11, *PLOS ONE*. 2016. p. e0152301. Available from:
357 <http://dx.doi.org/10.1371/journal.pone.0152301>
- 358 44. Green S, Higgins J, Alderson P, Clarke M, Mulrow CD, Oxman AD, et al. *Cochrane handbook for*
359 *systematic reviews of interventions*. West Sussex, England: John Wiley & Sons Ltd [Internet]. 2008;
360 Available from: [http://librariesbegan.info/cochrane-handbook-for-systematic-reviews-of-](http://librariesbegan.info/cochrane-handbook-for-systematic-reviews-of-interventions-to-spread-book-julian-p-t-higgins-sally-green-cochrane-collaboration.pdf)
361 [interventions-to-spread-book-julian-p-t-higgins-sally-green-cochrane-collaboration.pdf](http://librariesbegan.info/cochrane-handbook-for-systematic-reviews-of-interventions-to-spread-book-julian-p-t-higgins-sally-green-cochrane-collaboration.pdf)
- 362 45. Elsevier, Hylke Koers Phd And. New article type verifies experimental reproducibility [Internet].
363 Elsevier Connect. 2016 [cited 2019 Jul 17]. Available from: <https://www.elsevier.com/connect/new->

364 article-type-verifies-experimental-reproducibility

365 46. Vines TH, Albert AYK, Andrew RL, Débarre F, Bock DG, Franklin MT, et al. The availability of
366 research data declines rapidly with article age. *Curr Biol*. 2014 Jan 6;24(1):94–7.

367 47. Hardwicke TE, Ioannidis JPA. Populating the Data Ark: An attempt to retrieve, preserve, and
368 liberate data from the most highly-cited psychology and psychiatry articles. *PLoS One*. 2018 Aug
369 2;13(8):e0201856.

370

371

372

373

374

375

376

377

378


379

380

381

382

383 Figure 1: Flow Diagram of Included and Excluded Studies for the Reproducibility Analysis



385
386

Table 1: Types of Characteristics Associated with Reproducibility. Sample Sizes (N) depend on study type. Protocol about our measured characteristics is found online. (<https://osf.io/x24n3/>)

<i>Reproducibility Markers</i>		<i>The Importance of Each Marker in Regards with Transparency and Reproducibility.</i>
Accessibility		
All (N=300)	Article accessibility (Is the article available to the public without a paywall?)	Accessible research allows for a larger audience to assess and replicate a study's findings.
Funding		
Included studies (N=294)	Funding statement (Do authors provide a statement to describe if or how the study was funded?)	Including a funding statement provides greater transparency to readers. This increased transparency reveals any signs of bias or influence in the study's methodology.
Conflict of Interest		
Included studies (N=294)	Conflict of interest statement (Do the authors reveal any conflicts of interest in their manuscript?)	Conflict of interest statements give the authors a chance to be transparent about relationships with entities that may try to influence a study's findings.
Publication Citations		
Empirical studies† (N=171)	Systematic review/meta-analysis citations (Has the study been cited by data synthesis study designs such as systematic reviews or meta-analyses?)	Systematic reviews and meta-analyses synthesize information in studies that may have been replicated. The synthesis of information reveals a more complete answer to the question being investigated .
Analysis Scripts		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing the accessibility of the analysis script?)	Having the analysis script allows raw data to be analyzed exactly as the authors did in the original study, allowing others to replicate the data analysis correctly.
	Location of Analysis Script (Where can the analysis script be found? i.e. supplementary material)	
	Accessibility (Can a reader access the analysis script through the manuscript online or through other methods?)	

Materials		
Empirical studies¶ (N=162)	Availability statement (Is there a statement in the manuscript describing the accessibility of additional materials to the study?)	Additional materials allows readers to learn what is needed to reproduce the study, enabling the study to be replicated.
	Location of additional materials (Where can the additional material be found? ie. supplementary materials?)	
	Accessibility (Can a reader access additional material through the manuscript online or through other methods?)	
Pre-registration		
Empirical studies‡ (N=138)	Availability statement (Is there a statement in the manuscript describing whether the study was pre-registered or not?)	Pre-registering a study prevents any tampering of the study design throughout implementation of the study, increasing the reliability of the study. Also, pre-registration can provide components that may aid in replicating a study.
	Location of registration(Where was the study registered?)	
	Accessibility of the registration (Is the registration accessible?)	
	Components included in registration (What components of the study were found in the registration?)	
Protocols		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing whether the study protocol was available or not?)	Access to a detailed protocol allows others to know what, where, why, and how the study was performed, aiding others in the replication of the original study.
	Components (What components of the study were found in the protocol?)	
Raw Data		
Empirical studies‡ (N=171)	Availability statement (Is there a statement in the manuscript describing the accessibility of raw data from the study?)	Raw data provides insight into the author's thoughts and actions throughout implementation of the study, aiding others in replication of the original study. Additionally, raw data provides transparency to what is presented in the study's findings.
	Method of availability (Where can the raw data be found? ie. supplementary materials?)	

	Accessibility (Can a reader access raw data through the manuscript online or through other methods?)	
	Components (Are all the components of raw data that is needed to replicate the study available?)	
	Clarity (Is the raw data understandable?)	

† Empirical studies are studies with empirical data such as: clinical trial, cohort, case series, case reports, case-control, secondary analysis, chart review, commentaries (with data analysis), laboratory, and cross-sectional designs.

‡ Empirical studies that are case reports, case series, or studies without World of Science access were excluded from the reproducibility analysis (materials, data, protocol, and registration were excluded) as recommended by Hardwick et al[10].

¶ Empirical studies that are either case reports, case series, commentaries with analysis, meta-analyses, or systematic reviews were excluded as they are not expected to provide additional materials.

387

388

389

390

391

392

393

394

Table 2: Characteristics of Included Publications		
Characteristics		Variables
		N (%)
Funding (N=294)	University	4 (1.36%)
	Hospital	1 (0.34%)
	Public	23 (7.82%)
	Private/Industry	20 (6.80%)
	Non-Profit	2 (0.68%)
	Mixed	28 (9.52%)
	No Statement Listed	185 (62.93%)
	No Funding Received	31 (10.54%)
Type of Study (N=294)	No Empirical Data	115 (39.12%)
	Meta-Analysis	9 (3.06%)
	Chart Review	10 (0.34%)
	Clinical Trial	22 (7.48%)
	Case Study	6 (2.04%)
	Case Series	2 (0.68%)
	Cohort	94 (31.97%)
	Case Control	2 (0.68%)
	Survey	8 (2.72%)
	Laboratory	17 (5.78%)
	Other	9 (3.06%)
5 Year Impact Factor (N=274)	Median	2.466
	1st Quartile	1.898
	3rd Quartile	4.925
	Interquartile Range	1.898 - 4.925

395

396

Supplemental 1: Additional Characteristics of Reproducibility in Urology Studies			
Characteristics		Variables	
		N (%)	95% CI
Conflict of Interest Statement (N=294)	Statement, one or more conflicts of interest	36 (12.24%)	8.54 - 15.95
	Statement, no conflict of interest	163 (55.44%)	49.82 - 61.07
	No conflict of interest statement	95 (32.31%)	27.02 - 37.61
Data Availability (N=171)			
Data Availability (N=171)	Statement, some data are available	7 (4.09%)	1.85 - 6.34
	Statement, data are not available	2 (1.17%)	0 - 2.39
	No data availability statement	162 (94.74%)	92.21 - 97.26
Material Availability (N=162)			
Material Availability (N=162)	Statement, some materials are available	5 (3.09%)	1.13 - 5.04
	Statement, materials are not available	1 (0.62%)	0 - 1.50
	No materials availability statement	156 (96.30%)	94.16 - 98.43
Protocol Availability (N=171)			
Protocol Availability (N=171)	Full Protocol	1 (0.58%)	0 - 1.45
	No Protocol	170 (99.42%)	98.55- 100
Analysis Scripts (N= 171)			
Analysis Scripts (N= 171)	Statement, some analysis scripts area vailable	0 (0%)	-
	Statement, analysis scripts are not available	0 (0%)	-
	No analysis script availability statement	171 (100%)	-
Replication Studies (N= 171)			
Replication Studies (N= 171)	Novel study	170 (99.42%)	98.55 - 100
	Replication	1 (0.58%)	0 - 1.45
Open Access (N= 300)			
Open Access (N= 300)	Yes - found via Open Access Button	87 (29.00%)	23.87 - 34.13

	Yes - found article via other means	1 (0.33%)	0 - 0.99
	Could not access through paywall	212 (70.67%)	65.51 - 75.82
Cited in Systematic Review/ Meta-Analysis (a) (N=169)	No Citations	140 (82.84%)	78.57 - 87.11
	A Single Citation	20 (11.83%)	8.18 - 15.49
	One to Five Citations	9 (5.33%)	2.78 - 7.87
Abbreviations: CI, Confidence Interval. a - No studies were explicitly excluded from the systematic reviews or meta-analyses that cited the original article.			
Pre-Registration (N= 171)	Statement, says was pre--registered	8 (4.68%)	2.29 - 7.07
	Statement, says was not pre-registered	0	-
	No, there is no pre-registration statement	163 (95.32%)	92.93 - 97.71
Test Subjects (N= 294)	Animals	11 (3.74%)	-
	Humans	204 (69.39%)	-
	Neither	79 (26.87%)	-
Country of Journal Publication (N=294)	US	182 (61.90%)	-
	UK	34 (11.56%)	-
	Germany	2 (0.68%)	-
	India	11 (3.74%)	-
	Italy	3 (1.02%)	-
	Unclear	9 (3.06%)	-
	Other (a)	53 (18.03)	-
Country of Corresponding Author (N=294)	US	116 (39.46%)	-
	China	20 (6.80%)	-
	UK	14 (4.76%)	-
	Germany	10 (3.40%)	-
	Japan	13 (4.42%)	-

	France	6 (2.04%)	-
	Canada	14 (4.76%)	-
	Italy	24 (8.16%)	-
	India	2 (0.68%)	-
	Spain	5 (1.70%)	-
	Unclear	11 (3.74%)	-
	Other	59 (17.69%)	-

Supplemental 2: Additional Characteristics of Reproducibility in Urology Studies		
Characteristics		Variables
		N (%)
Material Availability (N=162)	Personal or institutional	0
	Supplementary information hosted by the journal	5
	Online third party	0
	Upon Request	0
	Yes, material was accessible	4
	No, material was not accessible	1
Data Availability (N=171)	Personal or institutional	0
	Supplementary journal information	7
	Online third party	0
	Upon Request	0
	Other (b)	0
	Yes, data could be accessed and downloaded	3
	No, data count not be accessed and downloaded	4
	Yes, data files were clearly documented	2
	No, data files were not clearly documented	1

	Yes, data files contain all raw data	0
	No, data files do not contain all raw data	3
	Unclear if all raw data was available	0
Pre-Registration (N=171)	Pre-registered on ClinicalTrials.gov	1
	Other (c)	7
	Yes, pre-registration was accessible	4
	No, pre-registration was not accessible	4
	Hypothesis was pre-registered	2
	Methods were pre-registered	1
	Analysis plan was pre-registered	0
Protocol (N=171)	Hypotheses was included in the protocol	0
	Methods were included in the protocol	0
	Analysis plan was included in the protocol	0